Maitake and Blood Pressure
21 mmHg
Whole maitake powder reduced systolic blood pressure by 21 mm Hg in spontaneously hypertensive rats over 35 days, the most-replicated preclinical result in maitake-hypertension research.
Preuss et al., Molecular and Cellular Biochemistry, 2002
4
rat models with consistent positive results
C-grade
blood pressure evidence rating (Natural Standard, 2009)
3 of 4
patients improved in the only human case series
Preuss et al., Molecular and Cellular Biochemistry, 2002
View as image ↗The most-cited number in maitake blood pressure research is 197 to 176 mm Hg. That 21 mm Hg drop in systolic pressure, measured by Preuss and colleagues in 2002 after 35 days of whole maitake powder in spontaneously hypertensive rats, became the headline result for this entire field. It has been replicated across four distinct animal models over 25 years. The question is what to make of it when no randomized human trial exists.
This article covers the complete evidence trail for maitake for hypertension: from the 1988 isolation of the first blood pressure-active fraction, through consistent animal results across multiple rat strains, to the only human data point available, a four-patient case series where three improved. For the broader science of how maitake works at the molecular level, see what maitake is and how it works.
Key Takeaways
- Preuss et al. (2002) found maitake whole powder reduced systolic BP from 197 to 176 mm Hg (p less than 0.001) in spontaneously hypertensive rats over 35 days
- Positive results span four distinct rat models: spontaneously hypertensive (SHR), Zucker fatty, aging female, and streptozotocin-diabetic
- The 2010 Preuss aging rat study confirmed the blood pressure system connection via a losartan challenge, showing maitake-treated rats had already-reduced renin-angiotensin tone before the drug was given
- The only human data comes from a four-patient case series cited in the 2009 Ulbricht systematic review; three of four patients with essential hypertension showed improvement
- The Natural Standard systematic review (Ulbricht 2009) assigned maitake a C-grade for blood pressure evidence: promising but not established
- Two 2023 systematic reviews confirm the preclinical evidence is consistent while noting the complete absence of controlled human trials
The Evidence in Summary: Consistent Animal Data, No Human Controlled Trial
Maitake research on hypertension sits at a specific point on the evidence ladder. The animal data is consistent and spans three decades. The human data is minimal and uncontrolled. No randomized controlled trial has been published.
Researchers have worked through four evidence layers for this topic. The first is mechanistic work, showing how maitake fractions interact with the enzymes and hormone systems that regulate blood pressure. The second layer is animal research: four rat models, multiple research groups, results pointing the same direction. The third layer is a single small case series in humans. The fourth layer, a controlled human trial, does not exist.
Preclinical evidence for maitake and hypertension is consistent across four rat models from 1987 to 2012, with systolic blood pressure reductions of 10 to 21 mm Hg. One uncontrolled case series found three of four patients with essential hypertension improving at approximately 3 to 5 grams per day. No randomized controlled trial of maitake for hypertension has been conducted. Animal studies used dosage ranges of 3 to 7 grams per day.[7]
The 2023 Rauf systematic review in Phytotherapy Research described maitake as a "promising antihypertensive functional food" based on the preclinical record, while explicitly noting the gap in human controlled data.[7]
Mechanistic Groundwork: What Lab Studies Show About the Blood Pressure Pathways
Before the animal results, it helps to understand what maitake is doing at the molecular level. The 2023 Rauf systematic review identifies the primary mechanisms relevant to blood pressure: ACE enzyme inhibition by ether-soluble fractions, suppression of the renin-angiotensin hormone system, nitric oxide enhancement by the SX-fraction, antioxidant activity, and potassium-mediated widening of blood vessels.[7]
The ACE pathway works like this. Blood pressure is partly controlled by a hormone called angiotensin II, which causes blood vessels to tighten. The enzyme ACE produces angiotensin II from an inactive precursor. Blocking ACE means less angiotensin II gets made, which means less vessel tightening. Maitake's ether-soluble fraction reduces the activity of ACE in the blood. Maitake also contains smaller protein-derived peptides that block ACE directly at the enzyme's active site.
The SX-fraction operates differently. It enhances nitric oxide production in the walls of blood vessels. Nitric oxide is a signaling molecule that tells smooth muscle cells in vessel walls to relax. This is separate from ACE inhibition, which is why maitake's antihypertensive effect probably comes from multiple converging pathways rather than a single compound.
These mechanistic pathways provide the biological rationale for interpreting the animal results below. For more on the specific compound classes and their documented effects, see the pharmacology of Grifola frondosa: how maitake works.
The Animal Record: Four Models, One Direction (1987 to 2010)
The animal literature on maitake and blood pressure begins in 1987 and accumulates through 2010. Four distinct rat models were tested by at least two independent research groups. The results are consistent.
The SHR Foundation: From First Evidence to Headline Numbers
Kabir and colleagues published the first evidence in 1987. In spontaneously hypertensive rats, a standard research model where animals develop high blood pressure genetically, dietary maitake mushroom reduced systolic blood pressure and also lowered total cholesterol and triglycerides in the blood. The same group returned in 1989 and replicated the result using maitake alone, confirming reduction in both systolic and diastolic blood pressure.[1][2]
The SHR model was used again in 2002. Preuss and colleagues tested whole maitake powder and its ether-soluble fraction in SHR rats over 35 days. Whole powder brought systolic pressure from 197 to 176 mm Hg, a 21 mm Hg reduction (p less than 0.001). The ether-soluble fraction alone produced comparable results. Preuss identified altered renin-angiotensin system activity as the primary mechanism, not coincidental blood pressure reduction through a different pathway.[3]
This 197-to-176 mm Hg result is the number that appears across competitor sites, supplement labels, and review articles. What most sources omit is the mechanistic confirmation that came eight years later.
The Zucker Fatty Rat Model: Extending to Obesity-Linked Hypertension
Talpur and colleagues ran a parallel study in 2002 using Zucker fatty rats. This is a different model from the SHR: Zucker fatty rats develop high blood pressure as part of an obesity-metabolic syndrome picture, not through genetic predisposition to essential hypertension. They tested two maitake fractions, the D-fraction and the SX-fraction. Both lowered blood pressure. The SX-fraction also improved insulin sensitivity and reduced triglyceride levels.[4]
The Zucker result matters for two reasons. First, it extended the blood pressure findings beyond a genetic hypertension model to one that more closely resembles the metabolic syndrome profile common in people with high blood pressure today. Second, the SX-fraction's simultaneous glucose and blood pressure effects suggest maitake's cardiovascular picture may be especially relevant in combined metabolic contexts. The cholesterol and atherosclerosis data are covered separately in the research on maitake and cardiovascular risk reduction.
The Losartan Experiment: Proving It Works Through the Blood Pressure System
In 2010, Preuss and colleagues published a study that answered the mechanism question more directly than any earlier work. They tested maitake extracts in aging female rats that were developing hypertension progressively over four months. Maitake stopped the blood pressure progression. But the critical finding was the losartan challenge.[5]
Losartan is a drug that blocks the receptor for angiotensin II, the hormone the renin-angiotensin system uses to tighten blood vessels. Here is the logic of the test. If maitake is already suppressing the renin-angiotensin system, then maitake-treated animals should have less of that system active. If they already have less of it active, then giving them losartan should produce a smaller blood pressure drop, because the system is already partially turned down.
That is exactly what happened. Rats that had been given maitake showed a smaller blood pressure response to losartan than untreated controls. Their blood pressure system was already running at lower levels. This experimental design is called a losartan challenge, and the result it produces here is the most direct evidence in this literature that maitake specifically modulates the renin-angiotensin pathway, not just blood pressure generally.
Preuss also measured serum ACE activity directly in these animals. Maitake-treated rats had lower ACE levels in their blood, confirming the reduction in enzyme activity that the earlier mechanistic research had suggested. The 2010 study also documented improvements in triglycerides and insulin sensitivity, extending the metabolic picture from the 2002 Zucker fatty work.
For the full renin-angiotensin story, including what the system does step by step and how different maitake fractions interact with it, see maitake and renin-angiotensin system modulation: blood pressure mechanisms. For the specific ACE peptide data, see Grifola frondosa and ACE inhibition.
The Only Human Data: Three Patients Improved, No Control Group
Translating animal blood pressure results to humans is not automatic. Blood pressure regulation involves more complex interactions in people, including lifestyle, diet, genetics, comorbidities, and medication history. A result in a rat model is a signal, not a guarantee.
The only direct human evidence for maitake and hypertension comes from a small case series documented in the 2009 systematic review by Ulbricht and colleagues, published in the Journal of the Society for Integrative Oncology as part of the Natural Standard Research Collaboration's comprehensive review of maitake evidence.[6]
The case series involved four patients with essential hypertension. Three of the four showed blood pressure improvement after dietary maitake use at approximately 3 to 5 grams per day. The fourth did not respond. The series was uncontrolled: no placebo group, no randomization, no blinding.
The Ulbricht review assigned maitake a C-grade for blood pressure evidence. In the Natural Standard grading system, C-grade means "unclear scientific evidence." There are data, but the quality is not sufficient to draw conclusions about benefit. This is an honest rating. It is not "no evidence," but it is also far from "established benefit."
No randomized controlled trial of maitake for hypertension has been published. The 2023 Zamora-Ros systematic review, which looked specifically at mushroom consumption and cardiometabolic outcomes in humans, confirmed this gap. Across observational and some interventional human studies, mushroom consumption as a food group was associated with improvements in blood pressure and lipid profiles. But maitake has not been tested in a controlled hypertension trial.[8]
Competitors who cite the 197-to-176 mm Hg result as evidence that maitake "lowers blood pressure in humans" are making a leap the data do not support. The animal result is real and consistent. The human translation is speculative.
What the 2023 Systematic Reviews Conclude About the Evidence State
Two major systematic reviews published in 2023 provide the most current assessment of where maitake and hypertension research stands.
Rauf and colleagues examined edible mushrooms as functional foods for hypertension management in Phytotherapy Research. The review confirmed ACE inhibition, renin-angiotensin system modulation, antioxidant activity, and potassium-mediated vasodilation as the documented mechanisms for maitake's blood pressure effects. The review described the preclinical evidence as consistent and the mechanism as well-characterized. On the human side, it described maitake and other edible mushrooms as "promising" while explicitly noting the absence of controlled clinical trials.[7]
Zamora-Ros and colleagues published a complementary review in Advances in Nutrition focused specifically on human evidence for mushroom consumption and cardiometabolic disease. Their analysis found associations between mushroom consumption and improved blood pressure and lipid biomarkers across observational and some interventional studies. The limitation is that most human studies did not isolate maitake specifically: they used various mushroom types, did not control for other dietary factors, and were observational in design. The causal chain from "maitake specifically" to "blood pressure lower in humans" has not been tested in a controlled study.[8]
The state of the evidence is this: a well-characterized mechanism, 25 years of consistent animal results across four models, and a human data gap that remains open.
Maitake's blood pressure effects share some mechanistic overlap with the cardiovascular protective effects linked to ergothioneine, a compound found in maitake that protects blood vessel walls from oxidative stress. See ergothioneine and endothelial function: vascular research for the endothelial protection angle.
What Doses Studies Used and Why Human Equivalents Remain Uncertain
The animal studies that produced blood pressure results used various forms and doses of maitake. Preuss and colleagues (2002) used whole maitake powder at doses that correspond to approximately 3 to 5 grams per day when scaled for rat body weight. The 2002 Talpur Zucker fatty study used specific concentrations of D-fraction and SX-fraction at measured doses. The 2010 Preuss aging study administered maitake extracts over four months and documented ongoing benefit.[3][4][5]
The human case series in the Ulbricht review involved approximately 3 to 5 grams of dietary maitake per day in the four patients who were observed.[6]
Extrapolating rodent doses to human doses requires scaling corrections, and those corrections are approximate. Different forms of maitake are not interchangeable. Whole dried powder, D-fraction extract, and SX-fraction have different compound concentrations and different activity profiles. The Preuss studies showed the ether-soluble fraction carried the strongest RAS-mediated blood pressure activity; the D-fraction was weaker on this measure.
No dose-ranging study in humans has identified a minimum effective dose for blood pressure. The 3 to 5 grams per day figure from the case series is the only human data point, and it comes from an uncontrolled observation of four people. What preparation, dose, and duration of treatment would produce consistent effects in a human population has not been tested. This is a key reason why the field is still waiting on an RCT.
For a broader overview of what is currently known about maitake and blood pressure across the research spectrum, see maitake and blood pressure: antihypertensive research.
The Bottom Line
Animal evidence for maitake and blood pressure reduction is consistent across four rat models and spans from 1987 to 2010, with the most rigorous study showing a 21 mm Hg systolic reduction and mechanistic confirmation via a losartan challenge. The only human data is a four-patient case series where three improved, rated C-grade by the Natural Standard systematic review. No randomized controlled trial has been conducted, and two 2023 systematic reviews confirm this gap remains open.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.